BioXcel presents at-home BXCL501 market opp: patients would use in 80% of episodes

BioXcel Therapeutics, Inc.

Market research shows ~3 episodes/month (36/year) per patient, vs prior 23M annual episodes estimate from claims data.
HCPs would prescribe BXCL501 for ~16% of their bipolar/schizophrenia patients based on target product profile.
Patients report they would use BXCL501 in 80% of at-home agitation episodes; pricing could reach $1,400+ per prescription.
At-home setting has no approved treatments; BXCL501 targets early intervention to prevent escalation.
SERENITY At-Home Phase 3 trial data (2,200+ episodes collected) results are upcoming.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.